Easy Find It Page
Easy Find It
Use Our Mobile Site
Use Our Mobile Site
Share This Website
Share
The Sugar Trehalose
Free NEWS Letter

Stay Up To Date - Subscribe Now

Affiliate Program
Untitled Document

Already an Affiliate? Click on the link below to access your account-

Affiliate Login
Endowment Book Store
The Trehalose Store
Endowment Store Front
Support The Endowment
Enter Amount:
We Accept
VisaMaster CardAmerican ExpressDiscoverssl lock
Download Store

Download Store

Download 7 Free Newsletters Plus Other Educational Materials
Main Menu
Home
- - - - - - -
Inside the Human Cell
The Sugar Trehalose
- - - - - - -
Sugar Science Forum
Glycomics Training
Interactive Glycomics Brochure
NEWS
7 FREE NEWSletters
HOT Links of Interest
- - - - - - -
Contact Us
Disclaimer
Sitemap
Educational e-textbook
Chapter One

Chapter One

FREE Sneek Peek
Chapter One
Evaluation Forms

Huntington’s General
Health Evaluation
FORM for Trehalose
Nutritional Pilot Survey

Parkinson's General
Health Evaluation
FORM for Trehalose
Nutritional Pilot Survey

Alzheimer / Dementia
General Health Evaluation
FORM for Trehalose
Nutritional Pilot Survey

Diabetic Health Evaluation
FORM for Trehalose
Nutritional Pilot Survey

General Public Health
Evaluation FORM for
Trehalose Nutritional
Pilot Survey (For General
Public without Huntington’s,
Alzheimer’s, or Parkinson’s.)
Who's Online
We have 32 guests online
50,000 implanted defibrillators recalled
INDIANAPOLIS � Guidant Corp. said Friday its implanted cardiac defibrillators used by 50,000 heart patients could be flawed and offered to replace more than half of them.  At least two patients with the devices have died, and the Indianapolis-based company said its devices had failed at least 45 times. Guidant said it was advising physicians about the safety of several models.
 
 The company said it would replace 28,900 of the implanted defibrillators if requested because the potential flaw couldn�t be fixed without removal. More than 20,000 of those are used by patients in the United States.
 
 Another 21,000 devices � 18,000 used by U.S. patients � can be fixed by external reprogramming, the company said.
 
 The U.S. Food and Drug Administration advised patients to see their doctor and said it would not recommend whether individual patients with one of the recalled devices should have them removed and replaced.
 
 Implantable defibrillators are intended to sense an irregular heart rhythm and shock the heart back into correct beating.
 
 The company said a programming change can be performed for the Prizm AVT, Vitality AVT and Renewal AVT devices at a physician�s office to reduce the risk of a short circuit, while defective Prizm 2 DR and Contak Renewal devices will be replaced at no charge.
 
 �Patient safety is paramount and our highest priority,� Guidant CEO Ronald W. Dollens said in a statement. �Guidant takes seriously its responsibility to create the most reliable products and services, enhance patient outcome and limit adverse events to patients.�
 
 Earlier this month, Guidant stood by its decision to continue selling the Prizm 2 DR for months after a potential flaw prompted a redesign, saying the original device was still reliable. 
 
In April, the company told doctors that the Prizm 2 DR defibrillator had failed in a small number of cases because of an electrical flaw. It also said that it had fixed the flaw in devices made after mid-2002.
 
 No failures in the Prizm 2 DR has been reported since April 2002. The faulty Contak Renewal defibrillators were manufactured on or before Aug. 26, 2004, Guidant said. 
 
A Pennsylvania man sued Guidant on June 1, claiming the company is financially liable to all patients implanted with one of its heart defibrillators because it did not tell them the devices could short-circuit. Lawyers for 74-year-old John Brennan said they hoped to make the legal complaint into a class-action lawsuit.
 
 Shares of Guidant fell 80 cents, or 1.1 percent, to $72.86 in afternoon trading on the New York Stock Exchange, where they have traded in a 52-week range of $49.95 to $75.15.
 
 Guidant shareholders in April voted overwhelmingly in favor of a planned $25.4 billion acquisition by Johnson & Johnson. The merger, which still must win regulatory approval in the United States and Europe, would be the largest business deal in the 119-year history of New Brunswick, N.J.-based health care products giant J&J. J&J has said it expects to complete the acquisition during the third quarter.

Associated Press

Source